3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Axsome Therapeutics Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

Business and financial performance

  • Q3 revenue $260M, equivalent to an annualized run rate above $1B for the first time; a milestone of ~$8.5M was recognized in the quarter.

  • AUVELITY revenue $208M, up 53% YoY versus 51% in Q2 and 15% sequentially; growth reflected MDD and accelerating Alzheimer’s disease agitation.

  • SUNOSI revenue ~$46M; SYMBRAVO revenue $3.9M, up QoQ, with continued growth expected.

  • Cash was $314M; Q3 was cash-flow positive for the first time, with a $13M net loss and ~$5M–$6M cash-flow profit excluding stock compensation and other one-time items.

AUVELITY growth and commercial execution

  • Alzheimer’s disease agitation NBRXs rose 3.6x, from ~1,000 monthly before approval to 3,600 monthly by late September; refills typically take a couple of quarters to catch up.

  • Total AUVELITY NBRXs increased from 2,400 weekly in Q1 to 3,000 in Q2, 3,550 in Q3 and 3,800 in October; management expects NBRX gains to feed future TRX growth.

  • The sales force expanded from ~270 to ~650 reps in roughly six months; management cited early returns in NBRXs and expects further optimization after the expansion.

  • MDD coverage reached 89% of covered lives, while all Medicare patients were covered, with the vast majority having no PA or step edit; long-term-care prescribing is expected to build through year-end and next year.

  • Q3 gross-to-net improved to the mid-to-high 40s; Q4 could see a tick up, and the 2027 quarterly pattern is expected to resemble 2026, subject to payer mix and coverage improvements.

  • Management expects continued robust AUVELITY growth, from underlying MDD momentum and accelerating agitation demand, without providing quarterly guidance.

Pipeline and upcoming milestones

  • The binge-eating-disorder study is fully enrolled, with top-line results expected in Q1; a positive primary-endpoint result would require a second adequate, well-controlled trial for an NDA or sNDA.

  • AXS-12 reboxetine review was more than halfway complete and tracking as expected, with a May 1 PDUFA date; pre-launch work is underway, leveraging the existing sleep team.

  • SUNOSI current indications have a stated peak-sales range of $300M–$500M and have grown low-to-mid-single digits sequentially with a largely unchanged sales team and marketing spend.

  • SUNOSI development includes CLARITY in MDD with excessive daytime sleepiness, with enrollment completion guided for next year; ADHD has two child/adolescent studies after a positive adult trial, while shift-work disorder requires one positive study to support filing.

  • Management expects 2027 to bring potential milestones and catalysts across multiple pipeline programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Axsome Therapeutics